Putman M, van Veen H W, Konings W N
Department of Microbiology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, NL-9751 NN Haren, The Netherlands.
Microbiol Mol Biol Rev. 2000 Dec;64(4):672-93. doi: 10.1128/MMBR.64.4.672-693.2000.
One of the mechanisms that bacteria utilize to evade the toxic effects of antibiotics is the active extrusion of structurally unrelated drugs from the cell. Both intrinsic and acquired multidrug transporters play an important role in antibiotic resistance of several pathogens, including Neisseria gonorrhoeae, Mycobacterium tuberculosis, Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Vibrio cholerae. Detailed knowledge of the molecular basis of drug recognition and transport by multidrug transport systems is required for the development of new antibiotics that are not extruded or of inhibitors which block the multidrug transporter and allow traditional antibiotics to be effective. This review gives an extensive overview of the currently known multidrug transporters in bacteria. Based on energetics and structural characteristics, the bacterial multidrug transporters can be classified into five distinct families. Functional reconstitution in liposomes of purified multidrug transport proteins from four families revealed that these proteins are capable of mediating the export of structurally unrelated drugs independent of accessory proteins or cytoplasmic components. On the basis of (i) mutations that affect the activity or the substrate specificity of multidrug transporters and (ii) the three-dimensional structure of the drug-binding domain of the regulatory protein BmrR, the substrate-binding site for cationic drugs is predicted to consist of a hydrophobic pocket with a buried negatively charged residue that interacts electrostatically with the positively charged substrate. The aromatic and hydrophobic amino acid residues which form the drug-binding pocket impose restrictions on the shape and size of the substrates. Kinetic analysis of drug transport by multidrug transporters provided evidence that these proteins may contain multiple substrate-binding sites.
细菌用来规避抗生素毒性作用的机制之一是将结构不相关的药物主动排出细胞。固有和获得性多药转运蛋白在包括淋病奈瑟菌、结核分枝杆菌、金黄色葡萄球菌、肺炎链球菌、铜绿假单胞菌和霍乱弧菌在内的几种病原体的抗生素耐药性中发挥着重要作用。开发不会被排出的新型抗生素或能阻断多药转运蛋白并使传统抗生素有效的抑制剂,需要详细了解多药转运系统对药物识别和转运的分子基础。本综述广泛概述了目前已知的细菌多药转运蛋白。基于能量学和结构特征,细菌多药转运蛋白可分为五个不同的家族。对来自四个家族的纯化多药转运蛋白在脂质体中的功能重建表明,这些蛋白能够介导结构不相关药物的输出,而无需辅助蛋白或细胞质成分。基于(i)影响多药转运蛋白活性或底物特异性的突变,以及(ii)调节蛋白BmrR药物结合结构域的三维结构,预测阳离子药物的底物结合位点由一个疏水口袋组成,其中埋藏着一个带负电荷的残基,该残基与带正电荷的底物发生静电相互作用。形成药物结合口袋的芳香族和疏水氨基酸残基对底物的形状和大小施加了限制。对多药转运蛋白药物转运的动力学分析提供了证据,表明这些蛋白可能含有多个底物结合位点。